For example, Dipeptidyl peptidase-4 (DPP-4) inhibitors are a recently developed class of antidiabetic pharmaceuticals that are garnering attention for their additional benefits, including enhanced pancreatic function, a reduced risk of hypoglycemia, and weight reduction. This evidence concerns the gene DPP4 and Hypoglycemia.